Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- PMID: 31562799
- DOI: 10.1056/NEJMoa1910962
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Abstract
Background: Niraparib, an inhibitor of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP), has been associated with significantly increased progression-free survival among patients with recurrent ovarian cancer after platinum-based chemotherapy, regardless of the presence or absence of BRCA mutations. The efficacy of niraparib in patients with newly diagnosed advanced ovarian cancer after a response to first-line platinum-based chemotherapy is unknown.
Methods: In this randomized, double-blind, phase 3 trial, we randomly assigned patients with newly diagnosed advanced ovarian cancer in a 2:1 ratio to receive niraparib or placebo once daily after a response to platinum-based chemotherapy. The primary end point was progression-free survival in patients who had tumors with homologous-recombination deficiency and in those in the overall population, as determined on hierarchical testing. A prespecified interim analysis for overall survival was conducted at the time of the primary analysis of progression-free survival.
Results: Of the 733 patients who underwent randomization, 373 (50.9%) had tumors with homologous-recombination deficiency. Among the patients in this category, the median progression-free survival was significantly longer in the niraparib group than in the placebo group (21.9 months vs. 10.4 months; hazard ratio for disease progression or death, 0.43; 95% confidence interval [CI], 0.31 to 0.59; P<0.001). In the overall population, the corresponding progression-free survival was 13.8 months and 8.2 months (hazard ratio, 0.62; 95% CI, 0.50 to 0.76; P<0.001). At the 24-month interim analysis, the rate of overall survival was 84% in the niraparib group and 77% in the placebo group (hazard ratio, 0.70; 95% CI, 0.44 to 1.11). The most common adverse events of grade 3 or higher were anemia (in 31.0% of the patients), thrombocytopenia (in 28.7%), and neutropenia (in 12.8%). No treatment-related deaths occurred.
Conclusions: Among patients with newly diagnosed advanced ovarian cancer who had a response to platinum-based chemotherapy, those who received niraparib had significantly longer progression-free survival than those who received placebo, regardless of the presence or absence of homologous-recombination deficiency. (Funded by GlaxoSmithKline; PRIMA/ENGOT-OV26/GOG-3012 ClinicalTrials.gov number, NCT02655016.).
Copyright © 2019 Massachusetts Medical Society.
Comment in
-
Personalized Medicine for Primary Treatment of Serous Ovarian Cancer.N Engl J Med. 2019 Dec 19;381(25):2471-2474. doi: 10.1056/NEJMe1914488. N Engl J Med. 2019. PMID: 31851805 No abstract available.
-
PARP Inhibitors in Ovarian Cancer.N Engl J Med. 2020 Apr 16;382(16):1572-1573. doi: 10.1056/NEJMc2000644. N Engl J Med. 2020. PMID: 32294361 No abstract available.
Similar articles
-
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.N Engl J Med. 2016 Dec 1;375(22):2154-2164. doi: 10.1056/NEJMoa1611310. Epub 2016 Oct 7. N Engl J Med. 2016. PMID: 27717299 Clinical Trial.
-
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial.Ann Oncol. 2024 Nov;35(11):981-992. doi: 10.1016/j.annonc.2024.08.2241. Epub 2024 Sep 14. Ann Oncol. 2024. PMID: 39284381 Clinical Trial.
-
Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.Lancet Oncol. 2019 Oct;20(10):1409-1419. doi: 10.1016/S1470-2045(19)30515-7. Epub 2019 Aug 29. Lancet Oncol. 2019. PMID: 31474354 Clinical Trial.
-
Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.Ann Pharmacother. 2020 Oct;54(10):1010-1015. doi: 10.1177/1060028020912749. Epub 2020 Mar 16. Ann Pharmacother. 2020. PMID: 32172572 Review.
-
Niraparib: A Review in Ovarian Cancer.Target Oncol. 2018 Aug;13(4):533-539. doi: 10.1007/s11523-018-0582-1. Target Oncol. 2018. PMID: 30073633 Review.
Cited by
-
Targeted radiopharmaceuticals: an underexplored strategy for ovarian cancer.Theranostics. 2024 Sep 30;14(16):6281-6300. doi: 10.7150/thno.99782. eCollection 2024. Theranostics. 2024. PMID: 39431018 Free PMC article. Review.
-
ARRDC3 as a Diagnostic and Prognostic Biomarker for Epithelial Ovarian Cancer Based on Data Mining.Int J Gen Med. 2021 Mar 22;14:967-981. doi: 10.2147/IJGM.S302012. eCollection 2021. Int J Gen Med. 2021. PMID: 33790626 Free PMC article.
-
Update on the secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: a narrative review.Ann Transl Med. 2021 Mar;9(6):510. doi: 10.21037/atm-20-4690. Ann Transl Med. 2021. PMID: 33850907 Free PMC article. Review.
-
Antibody-Drug Conjugates: The New Treatment Approaches for Ovarian Cancer.Cancers (Basel). 2024 Jul 15;16(14):2545. doi: 10.3390/cancers16142545. Cancers (Basel). 2024. PMID: 39061184 Free PMC article. Review.
-
Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system.Front Genet. 2022 Sep 9;13:886170. doi: 10.3389/fgene.2022.886170. eCollection 2022. Front Genet. 2022. PMID: 36159999 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical